The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...
Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...
Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of ...
Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...
Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
NK-CHAT may help detect antibody-mediated rejection earlier after kidney transplantation by measuring functional NK cell ...
Kirin has been granted a patent for a monoclonal antibody that binds to human CCR1, inhibiting its activation by CCL15. The antibody can be used in therapeutic and diagnostic agents for CCR1-related ...
An antibody (teal) bound to its target, the HIV protein Env (white and gray), also attaches to an immune cell via a receptor (red) on the immune cell’s surface. This interaction can activate the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results